మా గ్రూప్ ప్రతి సంవత్సరం USA, యూరప్ & ఆసియా అంతటా 3000+ గ్లోబల్ కాన్ఫరెన్స్ ఈవెంట్లను నిర్వహిస్తుంది మరియు 1000 కంటే ఎక్కువ సైంటిఫిక్ సొసైటీల మద్దతుతో 700+ ఓపెన్ యాక్సెస్ జర్నల్లను ప్రచురిస్తుంది , ఇందులో 50000 మంది ప్రముఖ వ్యక్తులు, ప్రఖ్యాత శాస్త్రవేత్తలు ఎడిటోరియల్ బోర్డ్ సభ్యులుగా ఉన్నారు.
ఎక్కువ మంది పాఠకులు మరియు అనులేఖనాలను పొందే ఓపెన్ యాక్సెస్ జర్నల్స్
700 జర్నల్స్ మరియు 15,000,000 రీడర్లు ప్రతి జర్నల్ 25,000+ రీడర్లను పొందుతున్నారు
María Adelina Jiménez-Arellanes, Gabriel Gutiérrez-Rebolledo, Susana Rojas-Tomé and Mariana Meckes- Fischer
Background: Tuberculosis is a global and serious Public Health problem due to the increase of multidrugresistant and extensively drug-resistant cases; as a result, diverse research groups worldwide are focusing their efforts on finding novel antituberculous agents that can provide greater effectiveness, less toxicity and having a specific mechanism of action, possibly being coadjuvants in the treatments currently prescribed.
Methods: The present review covers the literature published concerning secondary metabolites of those Mexican medicinal plants and secondary metabolites isolated from them showing in vitro antimycobacterial activity with MIC <50 μg/mL against sensitive and MDR M. tuberculosis strains as well as against NTM strains. The review also includes a special section for those natural compounds or plant extracts with antitubercular activity evaluated an in vivo experimental tuberculosis model.
Results: Some pure compounds with MIC<25 μg/mL are: 2-oxo-14-(3´,4´-methylenedioxyphenyl) tetradecane, 2- oxo-16-(3´,4´-methylenedioxyphenyl)hexadecane, 5,6-dehydro-7,8-dihydro methysticin, cepharanone B and piperolactam A (from Piper sanctum), suberosin (from Arracacia tolucensis) and leubethanol (from Leucophyllum frutescens). In addition, (-)-licarin A (from Aristolochia taliscana) was active against M. tuberculosis H37Rv, 12 MDR M. tuberculosis clinical isolates and four non-tuberculous mycobacteria. On the other hand, the antitubercular activity of (-)-licarin A, ursolic acid and oleanolic acid has been determined in a TB murine experimental in vivo model; (-)-licarin A reduces the bacterial lung load and the percentage of pneumonia in animals infected with M. tuberculosis H37Rv and MDR M. tuberculosis. The mixture of ursolic and oleanolic acids showed a significant reduction of bacterial loads and pneumonia in animals infected with M. tuberculosis H37Rv and MDR M. tuberculosis.
Conclusion: Since (-)-licarin A, ursolic acid and oleanolic acid have been evaluated as antitubercular compounds, these metabolites are candidates proposed feasible to be proposed for development of antituberculosis drugs.